CRBP CEO exercises options at $4.26, retains 138,187 shares

Rhea-AI Filing Summary

Corbus Pharmaceuticals (CRBP) CEO and director Yuval Cohen reported insider transactions on a Form 4. On 10/24/2025 and 10/27/2025, he exercised stock options at $4.26 per share and sold the same number of common shares under a Rule 10b5-1 trading plan adopted on March 14, 2025.

He exercised 18,660 options on 10/24 and sold 18,660 shares at a weighted average price of $17.01 (range $16.79–$17.38). He exercised 8,973 options on 10/27 and sold 8,973 shares at a weighted average price of $17.14 (range $17.00–$17.31).

Following these transactions, he beneficially owned 138,187 shares, which includes 123,561 unvested RSUs subject to vesting schedules. Remaining derivative holdings include 22,106 stock options at an exercise price of $4.26 expiring on 02/13/2033.

Insider Trade Summary

Net Seller: 27,633 shares ($471,204)

Net Sell 6 txns

Insider Cohen Yuval

Role Chief Executive Officer

Sold 27,633 shs ($471K)

Type	Security	Shares	Price	Value
Exercise	Stock options (right to buy)	8,973	$0.00	--
Exercise	Common Stock, par value $0.0001 per share	8,973	$4.26	$38K
Sale	Common Stock, par value $0.0001 per share	8,973	$17.14	$154K
Exercise	Stock options (right to buy)	18,660	$0.00	--
Exercise	Common Stock, par value $0.0001 per share	18,660	$4.26	$79K
Sale	Common Stock, par value $0.0001 per share	18,660	$17.01	$317K

Holdings After Transaction: Stock options (right to buy) — 22,106 shares (Direct); Common Stock, par value $0.0001 per share — 147,160 shares (Direct)

Footnotes (1)

1. This amount includes 123,561 unvested RSUs subject to each grant's vesting schedule as previously reported. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.79 to $17.38. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.31. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohen Yuval

(Last) (First) (Middle)

C/O CORBUS PHARMACEUTICALS HOLDINGS, INC

500 RIVER RIDGE DRIVE

(Street)

NORWOOD MA 02062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	10/24/2025		M		18,660	A	$4.26	156,847(1)	D
Common Stock, par value $0.0001 per share	10/24/2025		S(2)		18,660	D	$17.01(3)	138,187(1)	D
Common Stock, par value $0.0001 per share	10/27/2025		M		8,973	A	$4.26	147,160(1)	D
Common Stock, par value $0.0001 per share	10/27/2025		S(2)		8,973	D	$17.14(4)	138,187(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options (right to buy)(5)	$4.26	10/24/2025		M			18,660	02/13/2024	02/13/2033	Common Stock	18,660	$0	31,079	D
Stock options (right to buy)(5)	$4.26	10/27/2025		M			8,973	02/13/2024	02/13/2033	Common Stock	8,973	$0	22,106	D

Explanation of Responses:

1. This amount includes 123,561 unvested RSUs subject to each grant's vesting schedule as previously reported.

2. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025.

3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.79 to $17.38. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.31. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.

	/s/Yuval Cohen	10/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CRBP’s CEO report on Form 4?

Yuval Cohen exercised options at $4.26 and sold the resulting shares on 10/24/2025 and 10/27/2025 under a Rule 10b5-1 plan.

How many CRBP shares did the CEO sell and when?

He sold 18,660 shares on 10/24/2025 and 8,973 shares on 10/27/2025.

At what prices were the CRBP shares sold?

Weighted averages of $17.01 (range $16.79–$17.38) on 10/24 and $17.14 (range $17.00–$17.31) on 10/27.

Were the sales under a Rule 10b5-1 plan?

Yes. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 14, 2025.

How many CRBP shares does the CEO beneficially own after the trades?

He beneficially owned 138,187 shares, including 123,561 unvested RSUs subject to vesting.

What derivative securities remain after these transactions?

He holds 22,106 stock options at an exercise price of $4.26, expiring on 02/13/2033.